Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Revvity, Inc.

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Revvity is in Stage 2, the uptrend phase, now in week 18 (since Jun 18, 2026). It closed at $157.36, at its 52-week high and above its 200-day average, which is rising.

Revvity, Inc. provides health sciences solutions, technologies, and services. More about the company

$157.36
+0.48% today
$17.6B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is RVTY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S2 25w
S4 16w
S2 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 4w → S4 17w → S1 11w → S4 7w → S3 2w → S2 25w → S3 10w → S2 4w → S3 2w → S4 16w → S1 6w → S4 9w → S1 6w → S2 12w → S3 5w → S4 7w → S1 3w → S2 18w current
Total tracked: 165 weeks across 18 stage runs.

RVTY among Diagnostics & Research7th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
vs 52W High
0.0%
$82.21 lo$157.36 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 18
1w13w26w
Week 18, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
42.9%
200 DMA: $110.14 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.94x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+10.7%
3M
+42.4%
6M
+80.7%
YTD
+60.6%
1Y
+62.7%
Scan Membership
Breakout Watch
Latest: 2025-02-03
9 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 18 · Vol 0.94x
2026-10-21S2
Wk 18 · Vol 1.06x
2026-10-20S2
Wk 18 · Vol 0.75x
2026-10-19S2
Wk 17 · Vol 0.68x
2026-10-16S2
Wk 17 · Vol 0.72x
2026-10-15S2
Wk 17 · Vol 1.28x
2026-10-14S2
Wk 17 · Vol 1.08x
2026-10-13S2
Wk 17 · Vol 0.73x
2026-10-12S2
Wk 16 · Vol 0.59x
2026-10-09S2
Wk 16 · Vol 0.64x
2026-10-08S2
Wk 16 · Vol 0.76x
2026-10-07S2
Wk 16 · Vol 1.16x
Moving averages & range
50 DMA
$139.26
200 DMA
$110.14
52W High
$157.36
52W Low
$82.21
5D Low
$150.94
Resistance levels (recent highs)
20d High
$157.36
60d High
$157.36
120d High
$157.36
250d High
$157.36
Next resistance
Above all
P/E (TTM)
75.3
Forward 26.7
Earnings Growth (YoY)
+1.2%
Revenue +1.3%
ROE
+3.2%
Profit margin +8.2%
Dividend Yield
0.18%
P/B 2.4

Revvity: quick answers

What stage is Revvity in?

As of Oct 22, 2026, Revvity (RVTY) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 18, 2026 and is in week 18. What the four stages mean

Is Revvity in an uptrend?

Yes. Revvity is in a Stage 2 uptrend. It trades 42.9% above its 200-day average, which is rising.

How far is Revvity from its 52-week high?

Revvity closed at $157.36 on Oct 22, 2026, at its 52-week high. Its 52-week low is $82.21.

How has Revvity performed over the past year?

As of Oct 22, 2026, Revvity is up 62.7% over the past year and up 60.6% so far in 2026.

Which sector and industry is Revvity in?

Revvity is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.